Tykerb and Taxol for metastatic breast cancer

The Taxol and Tykerb combination has recently been shown to improve quality of life in metastatic breast cancer patients versus Taxol alone.  In a phase 3 randomized, multicenter, double-blind, placebo-controlled study, first-line therapy with Tykerb plus Taxol significantly improved clinical outcomes based on a pre-planned. The combination of investigational Tykerb (lapatinib) and Taxol (paclitaxel) as neoadjuant chemotherapy appears effective against inflammatory breast cancer, according to another small study. There are, as of yet in 2012, no published Phase III studies on survival for this regimen.

NCCN does not list the Taxol/Tykerb regimen.

Read the Professional version here.

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal